NSAID Trials and the Choice of Comparators — Questions of Public ... - New England Journal of Medicine (subscription)
January 24, 2007| NSAID Trials and the Choice of Comparators — Questions of Public ... New England Journal of Medicine (subscription), MA - Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and ... |
MediGene Initiates a Clinical Phase IIa Trial of RhuDex(R) in ... - PipelineReview.com (press release)
January 24, 2007| MediGene Initiates a Clinical Phase IIa Trial of RhuDex(R) in ... PipelineReview.com (press release), Spain - RhuDex® is a novel, orally available T cell co-stimulation modulator for the treatment of rheumatoid arthritis. By specifically blocking T-cell activation ... RhuDex Enters Clinical Phase IIa Trial in Rheumatoid Arthritis |
4SC nominates NFkB development candidate and presents new data - PipelineReview.com (press release)
January 24, 2007| 4SC nominates NFkB development candidate and presents new data PipelineReview.com (press release), Spain - The first project on the treatment of rheumatoid arthritis is currently undergoing clinical phase IIa. Three other product candidates are in pre-clinical ... Rheumatoid arthritis 4SC Nominates NFkB Development Candidate and Presents New Data at ... |
Safety Monitoring Board Recommends Continuation Of EntreMed's MKC ... - Medical News Today (press release)
January 24, 2007| Safety Monitoring Board Recommends Continuation Of EntreMed's MKC ... Medical News Today (press release), UK - ... cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. ... |
Roche's rheumatoid arthritis drug Actemra meets primary endpoint ... - Forbes
January 24, 2007| Roche's rheumatoid arthritis drug Actemra meets primary endpoint ... Forbes, NY - Actemra, through its unique blockade of the interleukin-6 receptor, will provide a new treatment option for people afflicted by rheumatoid arthritis,' Roche ... Phase III ACTEMRA(TM) (tocilizumab) Study Results Demonstrate ... Phase III ACTEMRA(TM) (tocilizumab) Study Results Demonstrate ... |
MediGene Initiates a Clinical Phase IIa Trial of RhuDex® in ... - WebWire (press release)
January 24, 2007| MediGene Initiates a Clinical Phase IIa Trial of RhuDex® in ... WebWire (press release), GA - RhuDex® is a novel, orally available T cell co-stimulation modulator for the treatment of rheumatoid arthritis. By specifically blocking T-cell activation ... RhuDex Enters Clinical Phase IIa Trial in Rheumatoid Arthritis |
4SC Nominates NFkB Development Candidate and Presents New Data at ... - Drug Newswire (press release)
January 24, 2007| 4SC Nominates NFkB Development Candidate and Presents New Data at ... Drug Newswire (press release), CT - The first project on the treatment of rheumatoid arthritis is currently undergoing clinical phase IIa. Three other product candidates are in pre-clinical ... Rheumatoid arthritis 4SC Nominates NFkB Development Candidate and Presents New Data at ... |